Emerging World Pharma focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers.
The investment would entitle Emerging World Pharma to an initial 10% of profits obtained from the marketing and distribution of generic pharmaceuticals sold. The company retains an option to increase the percentage of profit on additional investments of up to 25%.